The PRIME study is the clinical counterpart of the EARL study and it aims at mapping the pan-European clinical management of severe IDs and develop harmonised clinical case definitions, guidelines and pre-approved protocols for large multi-site clinical studies in Europe in response to severe ID outbreaks.
In March 2016, WP2 presented an E-poster "PREPARE'ing for (re) emerging infectious disease outbreaks: A review of European Clinical Management Guidelines on Acute, Community-acquired CNS infections" at the ECCMID congress in Amsterdam, The Netherlands.